FDA panel votes 6-2 in favor of daratumumab for high-risk smoldering multiple myeloma
The US Food and Drug Administration (FDA)’s Oncologic Drugs Advisory Committee (ODAC) voted 6-2 that the results from the phase 3 AQUILA trial
Multiple Myeloma
News
Ambassador Program
News
Society Updates
SOHO Israel 2025 wraps up successful 2-day event with leading hematologists
The third meeting of SOHO Israel and 9th International Davidoff conference, titled State of the Art and Next Questions, was held on May
Lymphoma
News
FDA ODAC votes 8-1 glofitamab trial does not apply to US patients
A federal advisory panel voted 8-1 Tuesday that results from the global STARGLO trial, which was intended as the confirmatory trial for full
News
SOHO Insider Podcast
Gwen Nichols speaks with Saad Usmani on CAR-T therapy advances
Saad Usmani, MD, of Memorial Sloan Kettering Cancer Center in New York, and Gwen Nichols, MD, CMO of the Leukemia & Lymphoma Society
Myelodysplastic Syndromes
Study identifies nonmutational p53 dysfunction as MDS risk factor
Even in patients with myelodysplastic syndromes (MDS) who don’t have a mutation in tumor protein 53 (p53), the p53 protein might still be
Leukemia
News
Video Interviews
Dr. Wu highlights global disparities in leukemia mortality
In this video, James Wu, MD, a hematology/oncology fellow at the Medical College of Wisconsin, discusses a letter published in the journal Leukemia
Leukemia
Video Interviews
Ching-Hon Pui, MD, on the global effort to treat pediatric leukemia
Dr. Pui, co-leader of the hematological malignancies program at the St. Jude Children’s Research Hospital in Memphis, Tennessee, shares his gratitude for receiving
Lymphoma
News
Bispecific–ADC duo yields responses in aggressive Burkitt’s lymphoma
Three patients with chemotherapy-refractory Burkitt’s lymphoma achieved complete metabolic responses after treatment with glofitamab and polatuzumab vedotin, according to a recently published correspondence
Cellular Therapy
2025 AACR Annual Meeting
Multiple Myeloma
Trispecific therapy ISB 2001 active in ongoing early myeloma trial
ISB 2001, a trispecific T-cell engager targeting BCMA and CD38, showed expected immune activity and no dose-limiting toxicities in an ongoing phase 1
Leukemia
2025 AACR Annual Meeting
News
RNA-seq maps genetic, nongenetic drivers of AML
Investigators used RNA sequencing to create a new gene activity atlas that showed how normal blood cells developed. The technique also identified the